Introduction
Cerebral ischemia/reperfusion (I/R) injury during stroke is the third leading cause of death worldwide with a mortality rate approaching 30% and a major cause of disability [1] . Much of the damage caused by cerebral IR injury is due to inflammatory processes affecting adjacent endothelial cell, neurons, and astrocytes, though the mechanisms associated with such inflammation have recently been characterized. In addition, increased plasma levels of neuropeptides (NP) following ischemic periods were shown to cause thrombosis or cerebral infarction. Inflammation may trigger leucocytes to release proteolytic enzymes, oxygen radicals, and active factors that alter TNF-毩 and IL-1 毬 levels [2] . Thus, it is an urgent need to develop advanced treatments for inflammation in affected patients.
Ferulic acid (FA), Puerarin(Pr) and Astragaloside(Al) are effective components in many natural medicine, and they were commonly Objective: To investigate the effects of the active ingredients combined therapy on inflammatory factors interleukin 1 beta (IL-1 毬 ) and neuropeptide Y (NPY) based on pharmacodynamics in rats. Methods: The animal model was built by transient middle cerebral artery occlusion (MCAO). The method for evaluating the concentrations of the FA-Pr-Al components in rat plasma was established by using HPLC and the expression levels of IL-1 毬 and NPY were determined by ELISA. A new mathematics method of the trend of percentage rate of change (PRC) was used to assess the correlation between pharmacokinetics (PK) and pharmacodynamics (PD). Results: FA-Pr-Al in combination reduced neurological deficits, decreased infarct volume and inhibited the expression levels of IL-1 毬 and NPY (all P<0.05) compared with the model group. FA, Pr and Al all displayed two compartment open models in rats. Clockwise hysteresis loops were obtained by time-concentration-effect curves. IL-1 毬 and NPY level changes in the plasma followed an opposite trend to the plasma concentration tendency after C max was reached. Astragaloside's PRC value was significantly higher than those of FA and puerarin between 120 to 180 min. Conclusions: The pharmacokinetics of FA-Pr-Al in combination were closely related its pharmacodynamics in treating ischemia/reperfusion injury, and the components of FA-Pr-Al may have a synergistic pharmacological effect. Astragaloside may play a more pronounced role in regulating IL-1 毬 and NPY levels compared with puerarin or FA. IF: 0.926 used for treating I/R injury in the clinical [3] . Due to the complex chemical composition of natural medicine ,classical quality control measures and characterization methods (pharmacokinetic/ pharmacodynamic, PK/PD) applied to purified chemical drugs were often not suited for the [4] . How to determine the effective components' action has become an important factor hindering the development of natural products [5] . Multiple studies have been recently focused on correlations between PK/PD and dose, concentration and time, which not only describe and predict the effects of a drug, but also can explore the mechanism of action of effective drugs [6] .
The current study aimed to assess the correlation between 
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FA-Pr-Al treatment
Pharmacokinetic studies
Pharmacokinetics and pharmacodynamics correlation analysis
Statistical analysis
All data were expressed as mean 依 standard deviation (SD).
Statistical analyses were performed with the SPSS 11.5 statistical software. One-way analysis of variance (ANOVA) and LSD post hoc methods were used to determine the significance of data sets. P values < 0.05 were considered statistically significant. (Table 1) . 
Results
Neurological deficits
Infarct volume
Infarct volume was significantly greater in the model group Positive control: Nimodipine group.
IL-1 毬 and NPY levels
The expression levels of IL-1 毬 and NPY were increased in model group rats' plasma compared with sham animals at all time points (all P<0.01),while the levels in FA-Pr-Al treatment group were decreased significantly at 60, 120, 180, 240, and 360 min (all P<0.01; Figure 2 ). 
Chromatographic separation and determination of FA-Pr-Al components
Pharmacokinetic parameter determination of FA-Pr-Al components
Pharmacokinetic parameters of ferulic acid, puerarin and astragaloside were summarized in ( Table 2) Notes: AUC was determined as area under the concentration versus time curve; C max , maximal concentration; T max was determined as the time when the maximal concentration reached; CLz/F, clearance; Vz/F, apparent volume of distribution; t 1/2z ; terminal half-life.
Time-concentration-effect curves
At the time points, concentration and effect did not display a strict one-to-one correspondence after oral administration. One plasma concentration of FA-Pr-Al corresponded to two kinds of efficacy, and maximal effects were lagged behind peaks of plasma concentration.
Notably, the time-concentration-effect curves were anticlockwise hysteresis loops between the plasma concentration of Ferulic acid and the levels of IL-1 毬 and NPY. However, clockwise hysteresis loops were obtained for time-concentration-effect curves between puerarin and astragaloside plasma concentrations and the levels of IL-1 毬 and NPY (Figure 4 ). T (min) Figure 5 . PRC( %) between two pharmacokinetic or pharmacodynamic points.
Pharmacokinetic and pharmacodynamic correlation analysis
The PRC was derived with the formula of (T 2 -T 1 )/T 1暳 100%. △T 1 represents two points from 5 min to 15 min of pharmacokinetics or pharmacodynamics respectively. △T 2 represents from 15 min to 30 min. △T 3 represents from 30 min to 60 min. △T 4 represents from 60 min to 120 min. △T 5 represents from 120 min to 180 min. △T 6 represents from 180 min to 240 min. △T 7 represents from 240 min to 360 min. Because of time lag of blood drug concentration, it is difficult to directly analyze the relationship between the pharmacokinetics and pharmacodynamics [11] .
Discussion
We have studied the correlation of pharmacokinetic and analysis method, which allows a more intuitive description of the correlation of PD/PK and helps us to determine the components that affect certain pharmacodynamic parameters from the cure graph.
From the trend chart the astragaloside metabolic rate decreased at a more pronounced level compared with FA and puerarin after blood concentration peaked, while pharmacodynamics of IL-1 毬 and NPY levels showed negligible changes in rats at the same time.
It is obvious that the opposite tendency between the changes of 毬 levels was also evident. These results suggest that IL-1 毬 may be a target of astragaloside or the latter may play a major role in IL-1 毬 homeostasis. Nevertheless, the change on the levels of NPY was not significant, suggesting that NPY may not a target of astragaloside, FA or puerarin.
This research was completed according to the "nature medicine indications Pharmacokinetics" guiding principles [12] . The idea was to identify the role of the compound in vivo and the metabolic mechanisms associated with the drug ingredients. This has been done by quantitatively describing the composition and efficacy in combination with the appropriate mathematical methods for assessing the relationship between them and the existing law. This mathematical method for PK-PD analysis allowed the identification of high correlation ingredients,thus the pharmaceutical ingredients obtained may be regarded as "indications of ingredients."
Furthermore, this mathematical method used for PK / PD analysis may also strongly correlate with unknown components, suggesting that the medicine may have other not yet detected component with strong pharmacological activity.
In FA-Pr-Al, the diverse components may have a synergistic pharmacological effect, which may be typical of nature medicine and its merits will be further investigated. Furthermore, astragaloside may play a more pronounced role in regulating IL-1 毬 and NPY levels compared with puerarin or FA. The mathematical method can be used to find a strong correlation ingredient for PK-PD analysis.
